Nasdaq ardx.

Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million. 31 thg 8, 2023 ... The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 8.59 / share. This is an increase of 18.82% from the prior ...WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Citigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...

AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ... Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.

Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ...WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...

31 thg 8, 2023 ... The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 8.59 / share. This is an increase of 18.82% from the prior ...AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Join the Nasdaq+ community for more personalized data, exclusive content, and market analysis. Try it today for $4.99/month. Subscribe Now.Nov 29, 2023 · See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...

Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...

View the latest Ardelyx Inc. (ARDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock. AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.Dec 1, 2023 · Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ... ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...Home ARDX • NASDAQ Ardelyx Inc Follow Share $4.37 Pre-market: $4.33 (0.92%) -0.040 Closed: Nov 30, 4:01:46 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Aurinia Pharmaceuticals Inc...ARDX Stock Overview ... Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal ...Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and ...

Private Advisor Group LLC bought a new stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report) during the 2nd quarter, according to its most recent 13F …FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …Nov 24, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ... WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023, the compensation committee of the company's …WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.

Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. The latest price target for . Ardelyx (NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023.The analyst firm set a price target for 11.00 …Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ETCompany ParticipantsCaitlin Lowie - Vice President of... Oct 31, 2023 seekingalpha.comDec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million. Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ...The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ... Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.

Here's what investors need to know. Shares of Ardelyx ( ARDX 7.44%) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. Ardelyx's ...

Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Ardelyx (NASDAQ:ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs.Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.31 thg 10, 2023 ... Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 ...May 17, 2023 · Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ... Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX.WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.10. 3 Months Ago. -$0.11. Ardelyx Inc. analyst estimates, including ARDX earnings per share estimates and analyst recommendations.Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Market Activity. Funds + ETFs. After-Hours Quotes. News + Insights. P/E & PEG Ratios. . Here you can find up-to-the-minute news and analysis of the company that you are researching for potential ... A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts.Consensus estimates suggest investors ...WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Instagram:https://instagram. igsbbest mobile online bankingformula for dividend yieldjon najarian cnbc Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock. The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ... genesis healthcare incfairmont paris See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. best time to sell stocks Back to ARDX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.According to 5 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $8.7, which is an increase of 92.91% from the latest price.